Aurora Kinase/Cdk Inhibitor 1PC X 5MG

Description General description A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC50 = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk′s (IC50 = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC50 in the range of 112 - 514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.). A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC50 = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk′s (IC50 = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC50 in the range of 112-514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.). Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target Aurora Kinase/Cdk Product competes with ATP. Reversible: yes Target IC50: 11 and 15 nM for Aurora-A, Aurora-B, respectively; 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively Packaging Packaged under inert gas Warning Toxicity: Harmful (C) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Emanuel, S., et al. 2005. Cancer Res.65, 9038. Lin R., et al. 2005. J. Med. Chem.48, 4208.